ADVIA Centaur<sup>®</sup> Her-2/Neu Shows Value in Monitoring Patients with Metastatic Breast Cancer

Lüftner, Diana; Cheli, Carol D.; Mickelson, K.; Sampson, E.; Possinger, K.

doi:10.1177/172460080401900301

Cited by 19 publications

(13 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although a rising tumor marker may be detected sooner than radiologically visible progression or than symptoms, available data do not indicate that this approach would lead to improved survival in patients with metastatic breast cancer. However, as novel targeted therapies are developed, specific assays such as the HER2/neu ECD may gain clinical utility [24]. …”

Section: Discussionmentioning

confidence: 99%

Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies

et al. 2005

View full text Add to dashboard Cite

Introduction The purpose of this retrospective study was to determine the clinical utility of serum HER2/neu in monitoring metastatic breast cancer patients undergoing trastuzumabbased therapy and to compare these results with those obtained using cancer antigen (CA) 15-3. We also sought to determine whether early changes in serum HER2/neu concentrations could be a predictor of progression-free survival.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies

et al. 2005

View full text Add to dashboard Cite

show abstract

“…HER2 consists of an extracellular binding domain, a transmembrane lipophilic segment and a functional intracellular tyrosine kinase domain (2). The HER2 extracellular domain excreted in serum can be quantitatively measured using an enzyme-linked immunosorbent assay or chemiluminescence immunoassay (3,4).…”

Section: Introductionmentioning

confidence: 99%

Serum HER2 levels and HER2 status in tumor cells in advanced gastric cancer patients

Sasaki

Fuse

Kuwata

et al. 2014

Japanese Journal of Clinical Oncology

View full text Add to dashboard Cite

Objective: Increased serum human epidermal growth factor receptor 2 levels have been found in metastatic breast cancer patients and are correlated with human epidermal growth factor receptor 2 overexpression in tumor cells. However, the prevalence of serum human epidermal growth factor receptor 2 in gastric cancer patients has not been elucidated. Methods: We retrospectively analyzed formalin-fixed paraffin-embedded tumor tissues and serum samples from 96 advanced gastric cancer patients. Human epidermal growth factor receptor 2 expression and gene amplification in tumor cells were determined by immunohistochemistry and fluorescence in situ hybridization. Serum human epidermal growth factor receptor 2 levels were measured using a chemiluminescent immunoassay. Human epidermal growth factor receptor 2 positivity in tumor cells was defined as immunohistochemistry 2+ with fluorescence in situ hybridization positive or immunohistochemistry 3+ with any fluorescence in situ hybridization results. Results: All tissue samples and serum samples were successfully measured. Nineteen patients (20%) were human epidermal growth factor receptor 2-positive in tumor cells. The median serum human epidermal growth factor receptor 2 level was 9.3 ng/ml (range, 5.0-332.4 ng/ml), and serum human epidermal growth factor receptor 2 levels were significantly separated according to human epidermal growth factor receptor 2 status in tumor cells (P < 0.0001, Wilcoxon's rank sum test); median serum human epidermal growth factor receptor 2 levels in human epidermal growth factor receptor 2-negative patients and -positive patients were 8.9 (range, 5.0-20.5) and 24.0 (range, 9.7-332.4), respectively. There were 15 serum human epidermal growth factor receptor 2-positive patients (16%) using a cutoff value of 15 ng/ml. The sensitivity and the specificity of serum human epidermal growth factor receptor 2 with respect to human epidermal growth factor receptor 2 positivity in tumor cells were 53 and 94%, respectively. Conclusions: Serum human epidermal growth factor receptor 2 measurements cannot be substituted for tissue human epidermal growth factor receptor 2 diagnosis in advanced gastric cancer patients. However, serum human epidermal growth factor receptor 2 levels are associated with human epidermal growth factor receptor 2 overexpression in tumor cells. Further investigations of clinical significance of serum human epidermal growth factor receptor 2 as a predictive marker and a therapy-monitoring marker are warranted.

show abstract

“…19,20 The Siemens Serum HER2 test measures the serum concentration of this protein using a CLIA method. 21,22 Since the measurement of serum HER2ECD levels is a simple, noninvasive and reproducible method, we assessed its availability as a biomarker for indicating the efficacy of anticancer treatment or for monitoring cancer status including progression or regression of cancer. According to a systemic review by Carney et al, 23,24 the positive rates of serum HER2ECD in primary and metastatic breast cancer were 18.5% (0-38) and 43% (23-80), respectively.…”

Section: Resultsmentioning

confidence: 99%

Clinical usefulness of human epidermal growth factor receptor-2 extracellular domain as a biomarker for monitoring cancer status and predicting the therapeutic efficacy in breast cancer

Kontani

Kuroda

Hashimoto

et al. 2013

Cancer Biology & Therapy

View full text Add to dashboard Cite

ADVIA Centaur^® Her-2/Neu Shows Value in Monitoring Patients with Metastatic Breast Cancer

Cited by 19 publications

References 25 publications

Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies

Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies

Serum HER2 levels and HER2 status in tumor cells in advanced gastric cancer patients

Clinical usefulness of human epidermal growth factor receptor-2 extracellular domain as a biomarker for monitoring cancer status and predicting the therapeutic efficacy in breast cancer

Contact Info

Product

Resources

About

ADVIA Centaur® Her-2/Neu Shows Value in Monitoring Patients with Metastatic Breast Cancer

Cited by 19 publications

References 25 publications

Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies

Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies

Serum HER2 levels and HER2 status in tumor cells in advanced gastric cancer patients

Clinical usefulness of human epidermal growth factor receptor-2 extracellular domain as a biomarker for monitoring cancer status and predicting the therapeutic efficacy in breast cancer

Contact Info

Product

Resources

About

ADVIA Centaur^® Her-2/Neu Shows Value in Monitoring Patients with Metastatic Breast Cancer